Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Classical hematology 2

Conditions

Neoplasms 14Pain 13Cancer Pain 6Breakthrough Pain 4Breakthrough Cancer Pain 3Chronic Pain 2Burns 2Anemia, Sickle Cell 2Agnosia 2Waldenstrom Macroglobulinemia 1Vulvar Neoplasms 1Vipoma 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Thymoma 1Thrombocythemia, Essential 1Testicular Neoplasms 1Stomach Neoplasms 1Standard Opioid Analgesic Treatment of Cancer-related Chronic Pain. 1Squamous Cell Carcinoma of Head and Neck 1Somatostatinoma 1Small Cell Lung Carcinoma 1Sezary Syndrome 1Sarcoma 1Salivary Gland Neoplasms 1Respiratory Insufficiency 1Rectal Neoplasms 1Quality of Life 1

Interventions

Fentanyl 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Burns × Fentanyl × Clear all
NCT00236041 2014-05-09

Efficacy/Safety Study of ACTIQ® for Opioid-Tolerant Children and Adolescents With Breakthrough Pain (BTP)

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 2 Completed
38 enrolled
Classical hematology

Agnosia, Anemia, Sickle Cell, Burns, Neoplasms, Breakthrough Pain

NCT00236093 2014-05-09

Extension Study of ACTIQ Treatment for Children and Adolescents With Breakthrough Pain

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 2 Completed
Classical hematology

Anemia, Sickle Cell, Burns, Neoplasms, Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡